The effect of oral folic acid on glutathione, glycaemia and lipids in Type 2 diabetes.
Plasma homocysteine is an established risk factor for vascular disease and precursor of the anti-oxidant glutathione. This study was designed to investigate the relationship of changes in homocysteine (Hcy) induced by oral folate to glutathione and measures of glycaemia and lipid metabolism in Type 2 diabetes (T2DM). Twenty-seven patients (26 male, 1 female, aged 48-68 years) with T2DM and microalbuminuria were treated with folic acid 10 mg daily for 3 months. During the study, diastolic blood pressure (p=0.04), HbA1c (p=0.04), serum triglycerides (p=0.04) and serum total/HDL-cholesterol ratio (p=0.004) all increased and serum HDL-cholesterol fell (p=0.006). The increased red cell folate correlated with a reduction in microalbuminuria (p=0.001). Overall, plasma glutathione increased (p=0.016) despite reduction in its precursor Hcy (p<0.001). Change in glutathione correlated inversely with change in HbA1c (p<0.02), total cholesterol (p=0.003) and triglycerides (p<0.02) and positively with HDL-cholesterol (p=0.033). Increase in glutathione correlated with levels of vitamin B6 (p<0.05). Metformin treatment protected against the rise in blood pressure (BP) (p=0.02), independently of changes in plasma glutathione. In summary, oral folic acid supplementation in T2DM reduced plasma Hcy and increased glutathione levels. HbA1c, triglycerides and HDL-cholesterol deteriorated during the trial: their levels correlated inversely with changes in glutathione. The increase in glutathione may depend on an adequate supply of B6, as changes in glutathione correlated with vitamin B6 levels. Reduced Hcy and increased glutathione may both mediate improvement in vascular function and outcome. Some aspects of the response to folate may be different in patients on metformin.
Child
D F
DF
Department of Medicine, Gladstone Centre, Maelor Hospital, Wrexham, North Wales, United Kingdom. sharon.langford@new-tr.wales.nhs.uk
Hudson
P R
PR
Jones
H
H
Davies
G K
GK
De
P
P
Mukherjee
S
S
Brain
A M
AM
Williams
C P
CP
Harvey
J N
JN
D000328:Adult; D000368:Aged; D000419:Albuminuria; D001786:Blood Glucose / Q000032:analysis*; D001794:Blood Pressure; D008076:Cholesterol, HDL / Q000097:blood; D003924:Diabetes Mellitus, Type 2 / Q000097:blood* / Q000188:drug therapy; D019587:Dietary Supplements; D004912:Erythrocytes / Q000737:chemistry; D005260:Female; D005492:Folic Acid / Q000008:administration & dosage*; D005978:Glutathione / Q000097:blood*; D006442:Glycated Hemoglobin / Q000032:analysis; D006710:Homocysteine / Q000097:blood; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage; D008055:Lipids / Q000097:blood*; D008297:Male; D008687:Metformin / Q000008:administration & dosage; D008875:Middle Aged; D014280:Triglycerides / Q000097:blood; D025101:Vitamin B 6 / Q000097:blood
D001786:Blood Glucose; D008076:Cholesterol, HDL; D005492:Folic Acid; D005978:Glutathione; D006442:Glycated Hemoglobin; D006710:Homocysteine; D007004:Hypoglycemic Agents; D008055:Lipids; D008687:Metformin; D014280:Triglycerides; D025101:Vitamin B 6